Naïve CD4 + CD25 − T cells activated in the presence of naïve splenic B cells may differentiate into CD4 + CD25 + Foxp3 − regulatory T cells, which were named Treg-of-B cells by our group (Table 1) . In addition, the oral delivery of antigenactivated naive Peyer's patch B cells induced Treg-of-B(P) cells with an increased suppressive function. 3 Our recent article reported that peritoneal B-1a cells produced more IL-10; moreover, B-1a cells promoted the induction of Treg-of-B1a cells in an IL-10-independent manner. 1 In our studies, splenic B2-cell-induced Treg-of-B cells, Peyer's patch B-cell-induced Treg-of-B (P) and peritoneal B-1a-cell-induced Treg-of-B1a cells shared similar phenotypes and functions. Our group subsequently reported that adoptive transfer these Treg-of-B cells protected mice from several disease models, including allergic asthma, rheumatoid arthritis and inflammatory bowel disease. Here, we summarize the suppression and induction mechanism of Treg-of-B cells (Figure 1 ).
We and other groups have demonstrated that antigen-presenting B cells may play a critical role in tolerance. Oral delivery of antigen-activated Peyer's patch B cells induced Treg-of-B(P) cells with enhanced suppressive ability. 3 Furthermore, oral delivery antigenactivated CD4 + CD25 + T cells, similar to B-cell-induced Treg-of-B cells, increased the levels of CTLA4, ICOS and PD1 and improved their suppressive functions. Both the oral delivery of antigen and adoptive transfer of single antigenspecific Treg-of-B cells protected mice from allergic asthma in antigen-specific and non-antigen-specific fashions. 2 Consistent with these findings, lentiviralenforced collagen peptide-presenting B cells protected mice from collageninduced arthritis, which may, in part, involve the induction of CD4 + regulatory T cells. 10 These studies indicated that B cells possess an ability to promote the generation of CD4 + regulatory T cells as part of the sophisticated tolerance mechanism.
Our results indicated that Treg-of-B cells were induced by monoclonal antibodies and specific peptides expressed as regulatory T-related markers, including inducible co-stimulator (ICOS and CD278), lymphocyte-activation gene 3 (LAG3), programmed cell death protein 1 (PD1 and CD279) and tumor necrosis factor receptor superfamily member 4 (TNFRSF4, OX40 and CD134). Recently, our group investigated the complex suppressive function of Treg-of-B cells. Treg-of-B cells produced higher levels of IL-10 and TGF-β and lower levels of IFN-γ and IL-2 than naïve CD4 + CD25 − T cells. 2 Treg-of-B1a cells exhibited a soluble-mediated suppression, whereas Treg-of-B cells appeared to rely more on cell-cell contactdependent suppression. 1 In the following studies, we reported that LAG3 was expressed on the Treg-of-B-cell surface and cooperated with IL-10 in the inhibitory mechanism. 4, 5 However, genetic IL-10-deficient Treg-of-B cells did not diminish their suppression in vitro or in vivo, which indicates that Treg-of-B cells possess an IL-10-independent suppressive ability. 7 We further determined that long-term Treg-of-B cells increased the expression levels of IL-10, IL-4, musculoaponeurotic fibrosarcoma oncogene homolog (c-Maf), cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and ICOS. IL-10 and CTLA4 play roles in the suppressive activity of long-term Tregof-B cells but not short-term Treg-of-B cells. 6 In contrast to IL-10-and CTLA4-mediated suppression of long-term Tregof-B cells, short-term Treg-of-B cells exert IL-10-independent and cell-cell contact-dependent inhibitory abilities. In addition to monoclonal antibodyinduced Treg-of-B cells, our group investigated the antigen specificity of Treg-of-B cells induced by a synthetic peptide and transgenic T cells bearing antigenspecific TCR. OVA 323-339 peptidepresenting naïve B-cell-induced DO11.10 naive T cells (in which transgenic TCR recognizes OVA 323-339 presented in H-2 d ) differentiated into Tregof-B cells, and single antigen-specific Treg-of-B cells exhibited inhibition in non-antigen-specific fashions in vitro. 2 We have demonstrated that the prophylactic transfer of Treg-of-B cells prevented the development of Th2-mediated allergic asthma, 2-4 Th1/Th17-mediated inflammatory bowel disease 7 and collagen-induced arthritis. 5 These findings demonstrated that Treg-of-B cells could exert suppressive functions both in vitro and in vivo.
It has been demonstrated that naïve B-T cells form a mature immunologic synapse during the generation of Tregof-B cells. 8 Our group has shown that cell-cell contact rather than IL-10 is important for the generation of Tregof-B cells. However, the IL-10 level was higher in a peritoneal B1a-T co-culture than that of a splenic B2-T co-culture. 1 The levels of IL-10, IL-4, IL-27 and TGF-β increased in long-term Treg-of-B-cell cultures, and IL-10 and IL-27 have been reported to promote the induction of Tr1 cells. Nevertheless, IL-10 and IL-27 blockade did not alter the generation of long-term Treg-of-B cells. The results of a transwell co-culture suggested that cell contact between B-T cells is required for the suppressive ability and phenotype of long-term Treg-of-B cells. 6 Another group reported that additional CD28 signaling broke the development of B-cell-induced regulatory T cells, which suggests the lack of or a low CD28 costimulation signal was essential. 9 These findings indicate that naïve B cells are able to promote CD4 + Foxp3 − regulatory T cells without supplemental cytokines or chemicals in a cell-cell contactdependent manner, and a fine-tuning costimulation signal is important for the generation.
In conclusion, we have induced and identified a particular subset of regulatory T cells stimulated by B cells. In addition, we have successfully applied these Treg-of-B cells to the treatment of allergic airway inflammation, a murine model of collagen-induced arthritis 
